Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
Hosted on MSN10d
MN Novo Nordisk settlement over insulin pricing [RAW]Minnesota Attorney General Keith Ellison announced a settlement with Novo Nordisk regarding the high price of insulin. The ...
Eli Lilly and Company will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a conference call that day with the investment ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
STORY: Shares of Eli Lilly jumped Thursday morning after the company, known for its popular weight-loss drug Zepbound, forecast annual profit largely above Wall Street estimates.The outlook appeared ...
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
2don MSN
John Lilly and the Earth Coincidence Control Office’ from Michael Almereyda and Courtney Stephens, narrated by Chloë Sevigny, debuts at Rotterdam, exploring the life of the utopian neuroscientist.
The Michael Almereyda and Courtney Stephens movie, narrated by Chloë Sevigny and premiering at the Rotterdam film festival, explores the life of the utopian neuroscientist who developed the isolation ...
Eli Lilly and Co. (LLY) on Thursday reported fourth-quarter earnings of $4.41 billion. The Indianapolis-based company said it had profit of $4.88 per share. Earnings, adjusted for one-time gains and ...
Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...
With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.
I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results